Gossamer Bio (GOSS) Amortization of Deferred Charges (2019 - 2026)
Gossamer Bio (GOSS) posted quarterly Amortization of Deferred Charges of $227000.0 for Q1 2026, down 5.81% year-over-year from $241000.0 in Q1 2025, and down 9.56% quarter-over-quarter from $251000.0 in Q4 2025.
Gossamer Bio (GOSS) Amortization of Deferred Charges (2019 - 2026) Analysis & Trends
Gossamer Bio's Amortization of Deferred Charges history runs 8 years deep, the most recent figure standing at $227000.0 for Q1 2026.
- In Q1 2026, Amortization of Deferred Charges fell 5.81% year-over-year to $227000.0; the TTM figure through Mar 2026 stood at $509000.0 (down 81.43% YoY), while the FY2025 annual figure was $985000.0, down 70.31% from the prior year.
- Amortization of Deferred Charges for Q1 2026 stood at $227000.0, down from $251000.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $2.5 million in Q4 2024, with the low at -$743000.0 in Q4 2023.
- The 5-year median for Amortization of Deferred Charges is $16000.0 (2025), against an average of $221647.1.
- The sharpest annual moves came in 2023 and 2024: Amortization of Deferred Charges plunged 375.19% in 2023, then jumped 432.44% in 2024.
- Gossamer Bio's Amortization of Deferred Charges stood at $270000.0 in 2022, then tumbled by 375.19% to -$743000.0 in 2023, then surged by 432.44% to $2.5 million in 2024, then tumbled by 89.84% to $251000.0 in 2025, then decreased by 9.56% to $227000.0 in 2026.
- Business Quant data shows GOSS's Amortization of Deferred Charges at $227000.0 in Q1 2026, $251000.0 in Q4 2025, and $16000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Gossamer Bio | 49.15 Mn | -7.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24,000.00 |
| Jun 30, 2026 | 24,000.00 |
| Mar 31, 2026 | 227,000.00 |
| Mar 31, 2026 | 227,000.00 |
| Dec 31, 2025 | 251,000.00 |
| Dec 31, 2025 | 251,000.00 |
| Sep 30, 2025 | 16,000.00 |
| Sep 30, 2025 | 16,000.00 |
| Jun 30, 2025 | 15,000.00 |
| Jun 30, 2025 | 15,000.00 |
| Mar 31, 2025 | 241,000.00 |
| Mar 31, 2025 | 241,000.00 |
| Dec 31, 2024 | 2.47 Mn |
| Dec 31, 2024 | 2.47 Mn |
| Sep 30, 2024 | 15,000.00 |
| Sep 30, 2024 | 15,000.00 |
| Jun 30, 2024 | 15,000.00 |
| Jun 30, 2024 | 15,000.00 |
| Mar 31, 2024 | 293,000.00 |
| Mar 31, 2024 | 293,000.00 |